摘要
目的:探讨米非司酮用于子宫内膜异位症患者保守性手术后巩固治疗的临床效果及不良反应。方法:子宫内膜异位症行保守性手术患者93例,分为米非司酮组33例,术后第1次月经来潮第1天开始服用10mg,1次/d,共6个月;促性腺激素释放激素激动剂(GnRH-a)组30例,腹壁皮下注射亮丙瑞林3.75mg,1次/月,共6次;对照组30例,术后未用药物治疗。结果:米非司酮组与GnRH-a组有效率分别为75.6%和80.0%,显著高于对照组56.7%(P<0.05);复发率分别为9.1%和6.6%,显著低于对照组40.0%(P<0.01);米非司酮组与GnRH-a组比较,差异无显著性意义(P>0.05)。结论:米非司酮用于子宫内膜异位症术后的巩固治疗有效、方便、廉价,不良反应少。
Objective： To evaluate the clinical effect and side effect of mifepristone in treatment of endometriosis after conservative operation. Methods ： Ninety-three women with endometriosis after conservative surgery were randomly divided into two groups ： mifepristone group （33 cases, mifepristone 10 mg/d, 6 months） ; gonadotropin releasing hormone agonist （GnRH-a） group （30 eases, hypodermically leuprorelin acetate 3.75 mg, once per twenty-eight days for 6 months）; control group （30 cases did not receive any postoperative medical treatment）. Results： Mifepristone group and GnRH-a group achieved similar significant relief of pelvic symptoms and signs （75.6% and 80%）, compared with the control group 56.7 % （P〈0. 05）. The cumulative recurrence rates of Mifeprlstone group and GnRH-a group were 9. 1% and 6.6%, significant lower than that of the control group 40. 0% （P〈0. 01）. There were no significant differences between Mifepristone and GnRH-a groups （P〈0. 05）. Conclusion：MifePristone seems to be an effective, safe and convenient treatment for endometriosis with low-cost, good compliance and few side effects.
出处
《华夏医学》
CAS
2008年第4期618-620,共3页
Acta Medicinae Sinica
